Ads
related to: acute leukemia survival rate- Safety
Learn More About Well Characterized
Safety Profile.
- Efficacy
Durable Complete Remissions
for R/R AML Patients.
- Access & Resources
Support is Available for
You and Your Patients.
- Dosing & Monitoring
Twice Daily
Oral Dosing.
- Safety
Search results
MD Anderson Research Highlights for June 5, 2024 | Newswise
Newswise· 1 day agoThe University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These
Autolus reports promising results for obe-cel in leukemia study By Investing.com
Investing.com· 6 days agoThe findings were presented at the American Society of Clinical..., the data revealed that the...
Novel CAR T therapy and shorter targeted therapy durations show promise for patients with leukemia
Medical Xpress· 6 days ago(ASCO) Annual Meeting. The novel anti-CD19 autologous chimeric antigen receptor (CAR) T cell therapy...
Experimental therapy shows promise in pancreatic cancer clinical trial
Medical Xpress· 5 days agoIt acts by inflaming the microenvironment surrounding the tumor and thereby augmenting the activity...
Kinder, Gentler Regimen for Classical Hodgkin Prevails in Randomized Trial
MedPage Today· 5 days agoReplacing chemotherapy with a targeted agent resulted in a better tolerated regimen for advanced...
Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal
Zacks via Yahoo Finance· 6 days agoGilead Sciences, Inc.'s (GILD) confirmatory TROPiCS-04 study on Trodelvy in locally advanced or...
Blenrep-Based Regimen Yields PFS Benefit in Relapsed/Refractory Myeloma
MedPage Today· 4 days agoProgression-free survival (PFS) was significantly higher with belantamab mafodotin (belamaf;...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 2 days agoLive from ASCO 2024 | Updated Data of Bcl-2 Inhibitor Lisaftoclax Combined with Azacitidine in Patients with AML Demonstrate Promising Efficacy and Manageable Safety PR Newswire SUZHOU, China ...
Understanding CAR T-cell therapy: A conversation with Northside’s Dr. Melhem Solh - Atlanta Business...
The Business Journals· 3 days agoDr. Melhem Solh, medical director of the cellular therapy program at Northside Hospital, answers...
Ad
related to: acute leukemia survival rate
